DAY 1

DAY 2

Speakers

PROGRAM

2 DAYS OF HIGH LEVEL CONFERENCES

The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.

CAR-T CELLS

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the revolutionized the disease course of patients with refractory/resistant refractory/resistant hematological malignancies. Based on these these unexpected and impressive results, the world of immunotherapy cellular immunotherapy offers new perspectives.

This session will cover a wide range of topics from research to understand mechanisms, production with alternative cell sources, to the clinic with feedbacks from the specific Spanish and from the productive Chinese models. Clinical management of innovative drugs in real life will also be discussed.

Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.

RNA

RNA is the basis for numerous therapeutic product manufacturing. Biologics, recombinant proteins, gene-modified cells, vaccines… all of these innovative therapies are somehow dependent on RNA. This session will cover different aspects of RNA manufacturing and applications in several settings like vaccines and biologics.

UPCOMING INNOVATIVE THERAPIES

This session will gather experts in the development of new cell therapies to the clinic.
Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.

REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES

This session will give exemples of the ATMP production ecosystem, with pre-industrial and industrial structures, and the challenges of financing these therapies.

We will also have a presentation of the regulatory guidelines defined for ATMPs and the new European regulation on clinical trials, by the European Medicines Agency and by the CAT (French Committee for Advanced Therapy Products).

Tuesday, September 20th

9:00-09:20 : Welcome and Introduction (Kursaal conf room)

Introductive words, Dr Sylvain Perruche, RIGHT Institute, Besançon, FR

Welcome words from the urban community’s President and the Region’s President

Introduction by Dr Marco Ruella, UPENN, Philadelphia, USA

 

9:20-12:30 : CAR-T Cells (Kursaal conf room)

Chairmen: Dr Christophe Ferrand and Dr Marina Deschamps, RIGHT Institute, Besançon, FR

 

09:20 : DECODING THE MODES OF ACTION OF CAR T CELLS USING INTRAVITAL IMAGING

Dr Philippe Bousso, Institut Pasteur and Inserm, Paris, FR

09:50 : Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

Dr Julien Valton, Cellectis, Paris, FR

10:20 : Pitch GOLD (Lumicks)

 

10:30 : BREAK

 

11:00 : Chinese experience and Landscape of  CART-cells in China

Pr Huang He, Bone Marrow Transplantation Center and Institute of Hematology , Zhejiang University, Hangzhou , PRC

11:30 : Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Spanish public/academic experience in CART in Acute Lymphoid Leukemia and Multiple Myeloma

Dr Álvaro Urbano Ispizua, Hospital Clínic de Barcelona, SP

12:00 : DESCAR-T Registry: Lessons learned from the French real-life database for CAR T cells in hematologic malignancies

Pr Roch Houot, UMR INSERM U1236, Rennes, FR

12:30 : Pitch GOLD (Cryoport Systems)

 

12:35-14:00 : Lunch (Kursaal Ballroom )

13:00-16:30 : B2B Meetings

14:00-16:15 : Visit of BioInnovation

16:00-16:30 : BREAK

 

16:30-19:30 : UPCOMING INNOVATIVE THERAPIES (Kursaal conf room)

Chairmen: Dr Sylvain Perruche, RIGHT Institute, Besançon, FR  

 

16:30 : Cell therapy in stroke 

Pr Olivier Detante, Grenoble Institute of Neuroscience, Grenoble, FR

17:00 : New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line

Eric Halioua, PDC*line Pharma, Liège, BE 

17:30 : Optimizing functions of adoptively transferred tumor-specific T cells

Dr Nathalie Labarriere , INCIT, UMR 1302, Nantes, FR

18:00 : Pitch GOLD (Flash Therapeutics)

18:05 : BREAK

18:30 :  Clinically Translatable Cytokine Factories for Cancer Immunotherapy

Dr Omid Veiseh, Rice University, Houston, USA

19:00 : Translation in cell and gene therapy : status, challenges and opportunities 

Dr Miguel Forte, ISCT, Charleroi, BE

20:00-23:30 : Evening reception (Kursaal Ballroom)

 

Wednesday, September 21st

9:00-12:00 : Regulation, Production and CLINICAL TRANSFER OF INNOVATIVE THERAPIES (KURSAAL CONF ROOM) 

Chairwoman: Dr Mathilde Girard, ADHARA, subsidiary of the URGO Group, Chenôve, and Dr Mathieu Guerriaud, CREDIMI, Dijon, FR

 

09:00 : Innovation Santé 2030 plan, how France can facilitate the development of innovative therapies ? Focus on the Biotherapy – Bioproduction Integrators network 

Emmanuel DEQUIER, « Grand défi Biomedicaments », Secrétariat Général pour l’Investissement, Paris, FR

9:30 : Accelerating Medical Innovation from Research to Patients

Andreas Wallnöfer, Jeito Capital, Paris, FR

 

10:00 : BREAK

 

10:30 : New Clinical Trials Regulation: European cooperation for innovation

Dr Claire Gérard, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Lyon, FR

11:00 : RNA-based Drugs and Regulation: Towards a Necessary Evolution of the Definitions Issued from the European Union Legislation 

Dr Mathieu Guerriaud, CREDIMI, Dijon, in collaboration with Pr Evelyne Kohli, INSERM LNC-UMR1231, Dijon, FR

11:30 : QUALITY CONTROL OF BIOLOGICAL ACELLULAR PRODUCTS: STANDARDIZATION OF EXTRACELLULAR VESICLE
METROLOGY

Dr Céline Elie-Caille, FEMTO-ST Institute, Besançon, FR

 

12:00-14:00 : Lunch (Kursaal Ballroom )

12:30-14:30  B2B meetings (Kursaal Ballroom)

 

14:30-17:00  RNA AS RAW MATERIELS & THERAPEUTICS  (Kursaal Conf room)

Chairman : Dr Philippe DULIEU, RD Biotech, Besançon, FR ; and Pr Olivier ADOTEVI, RIGHT Institute, Besançon, FR

 

14:30 : Messenger RNA-based therapeutics: Current status, opportunities and challenges

Pr Chantal Pichon, Center for Molecular Biophysics -UPR4301 CNRS, Orléans, FR

15:00 : MicroRNA as a tool for engineering next generation CAR T-cells

Dr Marco Alessandrini, Antion Biosciences, Geneva, CH

15:30 : BREAK

16:00 : A lentiviral platform for efficient and safe RNA delivery

Pascale Bouillé, Flash Therapeutics, Toulouse, FR

16:30 :  Moderna’s mRNA platform and applications to vaccines against infectious diseases

Dr Carole Henry, Moderna, Cambridge, Massachusetts, USA

 

17:00  : Conclusion End of Congress

17:15  : Beer Party

Join us and meet our speakers

Pr Olivier ADOTEVI – Right Institute (Besançon, FR), Dr Marco ALESSANDRINI – Antion Biosciences (Geneva, CH), Pascale BOUILLÉ – Flash Therapeutics (Toulouse, FR), Dr Philippe BOUSSO – Institut Pasteur (Paris, FR), Emmanuel DEQUIER – « Grand défi Biomedicaments » (Paris, FR), Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Pr Olivier DETANTE – Grenoble Institute of Neurosciences (Grenoble, FR), Dr Philippe DULIEU – RD Biotech (Besançon, FR), Dr Céline ELIE-CAILLE –FEMTO-ST Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Dr Miguel FORTE – Bone Therapeutics (Charleroi, BE), Claire GERARD – Agence nationale de sécurité du médicament et des produits de santé, ANSM (Lyon, FR), Dr Mathilde GIRARD – ADHARA, subsidiary of the URGO Group (Chenôve, FR), Dr Mathieu GUERRIAUD – CREDIMI (Dijon, FR), Eric HALIOUA– PDC*line Pharma (Liège-Belgium), Dr Carole HENRY – Moderna Cambridge (Massachusetts, USA), Pr Roch HOUOT – UMR INSERM U1236 (Rennes, FR), Pr HUANG HE – Institute of Hematology, Zhejiang University (Hangzhou, PRC), Nathalie LABARRIERE – INCIT, UMR 1302 (Nantes, FR), Dr Suman MITRA  INSERM (Lille, FR), Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Pr Marco RUELLA – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA), Phil CHALLIS – eTheRNA immunotherapies NV (Niel, Belgium),  Dr Álvaro URBANO ISPIZUA – Clínic de Barcelona (Barcelona, SP), Julien VALTON – Cellectis (Paris, FR), Dr Andreas WALLNÖFER – Jeito Capital (Paris, FR)

Speakers